

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

RECEIVED
SECRETARY OF THE SENATE
01 FEB 14 PM 3:27

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Akin, Gump, Strauss, Hauer & Feld, L.L.P.			
2. Address <input type="checkbox"/> Check if different than previously reported 1333 New Hampshire Avenue, NW			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country) DC 20036			
4. Contact Name Donald R. Pongrace	Telephone 202-887-4000	E-mail (optional)	5. Senate ID # 682-862
7. Client Name <input type="checkbox"/> Self Pfizer, Inc.	6. House ID # 31784036		

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report => Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES -- Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> => \$ <u>180,000</u> Income (nearest \$20,000)	EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> => \$ _____ Income (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options. <input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only <input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature _____

Printed Name and Title Donald R. Pongrace, Partner

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRA (one per page)

16. Specific lobbying issues

Potential legislation or regulation regarding use of certain antihistamines by operators of commercial vehicles


17. House(s) of Congress and Federal Agencies contacted Check if None

- U.S. House of Representatives
- U.S. Senate
- U.S. Department of Transportation

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Charles W. Johnson, IV		<input type="checkbox"/>
Susan H. Lent		<input type="checkbox"/>
Donald R. Pongrace		<input type="checkbox"/>
Henry A. Terhune		<input type="checkbox"/>
Rob Joyce		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date February 14, 2001
 Printed Name and Title Donald R. Pongrace, Partner

Registrant Name Akin, Gump, Strauss, Hauer & Feld, L.L.P. Client Name Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Legislation relating to Medicare prescription drug benefit, including Medicare Rx 2000 Act, H.R. 4680

17. House(s) of Congress and Federal Agencies contacted Check if None

U.S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Smith W. Davis		<input type="checkbox"/>
Karen E. Goldmeier		<input type="checkbox"/>
Gary A. Heinberg		<input type="checkbox"/>
Jorge Lopez, Jr.		<input type="checkbox"/>
Donald R. Pongrace		<input type="checkbox"/>
<i>Pana Singer</i>		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *Don Pongrace* Date February 14, 2001
Printed Name and Title Donald R. Pongrace, Partner